Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.
Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.
Fintel reports that on November 11, 2025, Wells Fargo maintained coverage of Keros Therapeutics (NasdaqGM:KROS) with a ...
Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 4 undervalued ...
Keros Therapeutics, Inc. ( NASDAQ:KROS ) defied analyst predictions to release its quarterly results, which were ...
Fintel reports that on November 6, 2025, Wedbush maintained coverage of Keros Therapeutics (NasdaqGM:KROS) with a Neutral ...
Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of ...
John Arcilla and Rochelle Pangilinan finally made their much-anticipated appearance as Hagorn and Agane on "Encantadia ...
An eclectic, high-end sale known as “Connoisseur’s Delight,” the event is led by a highly important Early Cycladic II Spedos Type marble idol of the ancient Greek Keros-Syros Culture, circa 1700-2300 ...
When raising capital in the U.S., owners and directors of foreign companies have to be cognizant of how restructuring can be used by creditors ...
Keros Therapeutics Inc. (KROS) presented additional clinical data from its Phase 1 trial of KER-065 at the American Society of ...
Keros Therapeutics remains a focal point in biotechnology discussions. The biotechnology segment continues to align with broad activity in nasdaq futures. Clinical developments reflect the sector’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback